RAPT Therapeutics IncNASDAQ:RAPT
- LAST PRICE2.7200
- TODAY'S CHANGE (%)-0.0700 (-2.5090%)
- Bid / Lots2.6100/ 3
- Ask / Lots2.8400/ 3
- Open / Previous Close2.7900 / 2.7900
- Day Range
- 52 Week Range
- Volume230,668
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RAPT |
|---|---|---|
| 09:32 ET | 4282 | 2.85 |
| 09:34 ET | 2019 | 2.82 |
| 09:36 ET | 300 | 2.79 |
| 09:38 ET | 250 | 2.8152 |
| 09:39 ET | 2850 | 2.78 |
| 09:41 ET | 350 | 2.775 |
| 09:43 ET | 300 | 2.785 |
| 09:45 ET | 200 | 2.79 |
| 09:50 ET | 1300 | 2.78 |
| 09:54 ET | 494 | 2.75 |
| 09:56 ET | 100 | 2.74 |
| 09:57 ET | 372 | 2.74 |
| 09:59 ET | 1736 | 2.76 |
| 10:01 ET | 680 | 2.76 |
| 10:03 ET | 1936 | 2.74 |
| 10:08 ET | 551 | 2.75 |
| 10:10 ET | 825 | 2.755 |
| 10:12 ET | 1026 | 2.75 |
| 10:14 ET | 2200 | 2.76 |
| 10:15 ET | 400 | 2.76 |
| 10:17 ET | 2497 | 2.785 |
| 10:19 ET | 982 | 2.81 |
| 10:21 ET | 1074 | 2.82 |
| 10:24 ET | 303 | 2.84 |
| 10:26 ET | 300 | 2.84 |
| 10:28 ET | 408 | 2.84 |
| 10:30 ET | 800 | 2.82 |
| 10:33 ET | 501 | 2.826 |
| 10:35 ET | 300 | 2.82 |
| 10:37 ET | 500 | 2.81 |
| 10:39 ET | 100 | 2.81 |
| 10:46 ET | 700 | 2.8 |
| 10:48 ET | 200 | 2.79 |
| 10:50 ET | 200 | 2.78 |
| 10:51 ET | 1021 | 2.81 |
| 10:57 ET | 600 | 2.78 |
| 11:00 ET | 400 | 2.79 |
| 11:02 ET | 300 | 2.78 |
| 11:04 ET | 100 | 2.79 |
| 11:08 ET | 200 | 2.79 |
| 11:11 ET | 3638 | 2.8 |
| 11:15 ET | 200 | 2.79 |
| 11:18 ET | 616 | 2.7805 |
| 11:20 ET | 3337 | 2.78 |
| 11:22 ET | 1501 | 2.78 |
| 11:24 ET | 4206 | 2.78 |
| 11:26 ET | 3521 | 2.78 |
| 11:31 ET | 1084 | 2.75 |
| 11:33 ET | 8703 | 2.72 |
| 11:36 ET | 600 | 2.72 |
| 11:38 ET | 200 | 2.71 |
| 11:40 ET | 932 | 2.71 |
| 11:42 ET | 1300 | 2.72 |
| 11:44 ET | 301 | 2.71 |
| 11:45 ET | 308 | 2.7 |
| 11:47 ET | 609 | 2.7 |
| 11:49 ET | 4623 | 2.69 |
| 11:51 ET | 1814 | 2.69 |
| 11:54 ET | 180 | 2.69 |
| 11:56 ET | 300 | 2.69 |
| 11:58 ET | 3159 | 2.68 |
| 12:00 ET | 200 | 2.69 |
| 12:02 ET | 574 | 2.68 |
| 12:03 ET | 5599 | 2.69 |
| 12:05 ET | 200 | 2.69 |
| 12:07 ET | 720 | 2.695 |
| 12:09 ET | 1949 | 2.69 |
| 12:12 ET | 854 | 2.68 |
| 12:14 ET | 2150 | 2.68 |
| 12:16 ET | 500 | 2.68 |
| 12:18 ET | 6421 | 2.7 |
| 12:20 ET | 911 | 2.7 |
| 12:21 ET | 200 | 2.7 |
| 12:23 ET | 2525 | 2.7262 |
| 12:25 ET | 1925 | 2.72 |
| 12:30 ET | 200 | 2.72 |
| 12:32 ET | 219 | 2.721 |
| 12:34 ET | 6730 | 2.73 |
| 12:36 ET | 217 | 2.73 |
| 12:38 ET | 300 | 2.72 |
| 12:39 ET | 300 | 2.72 |
| 12:41 ET | 3989 | 2.72 |
| 12:43 ET | 200 | 2.72 |
| 12:45 ET | 4887 | 2.72 |
| 12:48 ET | 900 | 2.72 |
| 12:50 ET | 801 | 2.72 |
| 12:52 ET | 500 | 2.72 |
| 12:54 ET | 3181 | 2.735 |
| 12:56 ET | 3223 | 2.72 |
| 12:57 ET | 4458 | 2.725 |
| 12:59 ET | 42144 | 2.72 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
RAPT Therapeutics Inc | 94.7M | -0.9x | --- |
Eledon Pharmaceuticals Inc | 94.7M | -1.7x | --- |
X4 Pharmaceuticals Inc | 94.8M | -0.8x | --- |
Boundless Bio Inc | 94.4M | 0.0x | --- |
Relmada Therapeutics Inc | 90.8M | -1.0x | --- |
Athira Pharma Inc | 98.5M | -0.8x | --- |
Company Information
RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. Utilizing its drug discovery and development engine, it develops selective small molecules designed to modulate the critical immune responses underlying these diseases. Its lead inflammation drug candidate, zelnecirnon (RPT193), and its lead oncology drug candidate, tivumecirnon (FLX475), each target C-C motif chemokine receptor 4 (CCR4), a drug target that potentially has broad applicability in inflammatory diseases and oncology. Its inflammation drug candidate, zelnecirnon, is designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its oncology drug candidate, tivumecirnon, is designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors.
Contact Information
- Headquarters
- 561 Eccles AveSOUTH SAN FRANCISCO, CA, United States 94080-1906
- Phone
- 650-489-9000
- Fax
- 302-531-3150
Executives
- Independent Chairman of the Board
- William Rieflin
- President, Chief Executive Officer, Director
- Brian Wong
- Chief Financial Officer
- Rodney Young
- Chief Scientific Officer
- Dirk Brockstedt
- Chief Medical Officer
- William Ho
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $94.7M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 34.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.22 |
EPS | $-3.07 |
Book Value | $4.27 |
P/E Ratio | -0.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
